Five-year post-vaccination efficacy of hepatitis B vaccine in rural Nigeria

Human Vaccines

Volumn 7, Issue 6, 2011, Pages 625-629

  Odusanya, Olumuyiwa O ^a   Alufohai, Ewan ^b   Meurice, François P ^c   Ahonkhai, Vincent I ^d,e  

^a LAGOS STATE UNIVERSITY   (Nigeria)

^b AMBROSE ALLI UNIVERSITY   (Nigeria)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d GLAXOSMITHKLINE   (United States)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Geometric mean concentration; Hepatitis B virus; Immunity; Protection; Vaccination; Vaccine efficacy

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NIGERIA; PRESCHOOL CHILD; RURAL POPULATION; SCHOOL CHILD;

CHILD; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; NIGERIA; VACCINATION;

EID: 79959346612     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.6.14990     Document Type: Article

References (27)

1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28:112-25. (Pubitemid 44289094)
2. Mbaawuaga EM, Enenebeaku MNO, Okopi JA, Damen JG. Hepatitis B virus (HBV) infection among pregnant women in Makurdi, Nigeria. Afr J Biomed Res 2008; 11:155-9.
3. Forbi JC, Onyemauwa N, Gyar SD, Oyeleye AO, Entonu P, Agwale SM. High prevalence of hepatitis B virus among female sex workers in Nigeria. Rev Inst Med Trop Sao Paulo 2008; 50:219-21.
4. Egah DZ, Banwat EB, Audu ES, Iya D, Mandong BM, Anele AA, et al. Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria. East Mediterr Health J 2007; 13:961-6. (Pubitemid 47505620)
5. Ndako JA, Echeonwu GON, Olabode AO, Nwankiti OO, Aimakhu SO, Onovoh SA, et al. Seroprevalence of hepatitis B surface antigen (HBsAg) among children of primary school age in a community, North-central Nigeria. Sierra Leone J Biomed Res 2010; 2:32-7.
6. Ashir GM, Rabasa AI, Gofama MM, Bukbuk D, Abubakar H, Farouk GA, Study of hepatic functions and prevalence of hepatitis B surface antigenaemia in Nigerian children with human immunodeficiency virus infection. Niger J Med 2009; 18:260-2.
7. World Health Organization (WHO). Hepatitis B Vaccine, WHO position paper. Available from http://www.who.int/wer/2009/wer8440.pdf. Accessed January 13, 2010.
8. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34:1329-39. (Pubitemid 41819540)
9. Girisha KM, Kamat JR, Nataraj G. Immunolgical response to two hepatitis B vaccines administered in two different schedules. Indian J Pediatr 2006; 73:489-91. (Pubitemid 44319458)
10. Adoga MP, Pennap G, Akande BO, Mairiga JP, Pechulano S, Agwale SM. Evaluation of a recombinant DNA hepatitis B vaccine in a vaccinated Nigerian population. J Infect Dev Ctries 2010; 4:740-4.
11. Jafarzadeh A, Montazerifar SJ. Persistence of antihbs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub MedColl Abbottabad 2006; 18:4-9.
12. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow up. Ann Intern Med 2005; 142:333-41. (Pubitemid 40293406)
13. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hulburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow up study and response to a booster dose. J Infect Dis 2009; 200:1390-6.
14. Odusanya OO, Alufohai JE, Meurice FP, Clemens R, Ahonkhai VI. Low immunization coverage in rural Nigeria. Nig Q J Hosp Med 2000; 10:118-20.
15. Odusanya OO, Alufohai JE, Meurice FP, Clemens R, Ahonkhai VI. Short-term evaluation of a rural immunization program in Nigeria. Journal of the National Medical Association 2003; 95:175-9. (Pubitemid 37099559)
16. Odusanya OO, Alufohai FE, Meurice FP, Wellens R, Weil J, Ahonkhai VI. Prevalence of hepatitis B surface antigen in vaccinated children and control in rural Nigeria. Int J Infect Dis 2005; 9:139-43. (Pubitemid 40523758)
17. Odusanya OO, Alufohai EF, Meurice FP, Ahonkhai VI. Determinants of vaccination coverage in rural Nigeria. BMC Public Health 2008; 8:381.
18. Forbi JC, Vaughan G, Purdy MA, Campo DS, Xia Gi, Ganova-Raeva LM, et al. Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria. PLoS one 2010; 5:11615.
19. Ugwuja E, Ugwu N. Seroprevalence of hepatitis B surface antigen and liver function tests among adolescents in Abakaliki, South eastern Nigeria. The Internet Journal of Tropical Medicine 2009; 6:1.
20. Adoga MP, Gyar SD, Pechulano S, Bashayi OD, Emiasegen SE, Zungwe T, et al. Hepatitis B virus infections in apparently healthy urban Nigerians: data from pre-vaccination tests. J Infect Dev Ctries 2010; 4:397-400.
21. Odusanya OO, Meurice FP, Hoet B. Nigerian medical students are at risk for hepatitis B infection. Trans R Soc Trop Med Hyg 2007; 101:465-8. (Pubitemid 46394273)
22. Ola SO, Otegbayo JA, Yakubu A, Aje AO, Odaibo GN, Shokunbi W. Pitfalls in diagnosis of hepatitis B virus infection among adult Nigerians. Niger J Clin Pract 2009; 12:350-4.
23. nd year of life. BMC Infect Dis 2010; 10:9.
24. Ijoma U, Nwokediuko S, Onyenekwe B, Ijoma C. Low prevalence of hepatitis B 'E' antigen in asymptomatic adult subjects with hepatitis B virus infection in Enugu, South east Nigeria. The Internet Journal of Gastroenterology 2010; 10:1.
25. Kukka C. What is HBV DNA and how is it measured? Available from http://www.hbvadvocate.org/hepatitis/hepb/measure-DNA.html. Accessed on December 25, 2010.
26. Davis AR, Rosenthal P. Hepatitis B in children. Pediatr Rev 2008; 29:111-20.
27. World Health Organization (WHO). Expert Committee on Biological Standardization. Report of a WHO collaborative study to assess the suitability of a candidate international standard for antibody to pandemic H1N1 influenza virus. WHO/BS/10.2137.